News
Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral
UK MHRA Grants GenSight Biologics’ LUMEVOQ® Ophthalmic Gene Therapy Promising Innovative Medicine Designation
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
QIAGEN steigt in den deutschen Leitindex DAX auf
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass das Unternehmen in den DAX (Deutscher Aktienindex), den führenden deutschen Börsenindex, aufgenommen wurde.
"Die
QIAGEN to Enter the DAX – Germany’s Leading Stock Market Index
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has been chosen to be included in the DAX (Deutscher Aktienindex), the leading German stock market index in Germany.
Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On September 2
Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
Pfizer Inc. (NYSE:PFE) today announced the initiation of RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease), a Phase 3 clinical trial evaluating the efficacy
Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that Ashley Cordova, Chief Financial Officer, and Pritesh Shah, Chief Commercial Officer, will participate in the 2021 Wells Fargo Virtual Healthcare
ICON plc to Present at the Wells Fargo 16th Annual Healthcare Conference and the Baird Global Healthcare Conference
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at:
-
the Wells Fargo
Transgene Participates in New Cancer Research Consortium
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces its participation in the launch of
Novocure Appoints Bill Burke as Chief Human Resources Officer
Novocure (NASDAQ: NVCR) today announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021. This appointment reflects the importance of
IMV Inc. to Present at Three Investor Conferences in September
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that members of IMV’s
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences:
-
2021 Virtual
GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210830005575/en/
Figure 1. Evolution of best-corrected visual acuity
Vifor Pharma’s Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelines
Regulatory News:
Vifor Pharma is pleased to announce that the European Society of Cardiology (ESC) included new recommendations and proposals in the 2021 ESC guidelines for the diagnosis and
Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that JADE DARE (B7451050), a 26-week, randomized, double-blind, double-dummy, active-controlled, multi-center Phase 3 study, met its co-primary and key
Lysogene Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today announced dosing of the first patient in
Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
- Firibastat is as efficent as the current standard of care
Pfizer Announces New Chief Business Innovation Officer
Pfizer Inc. (NYSE: PFE) today announced that Aamir Malik has joined the company as Executive Vice President and Chief Business Innovation Officer. Mr. Malik will be a member of Pfizer’s Executive
Pfizer and BioNTech Announce Collaboration With Brazil’s Eurofarma to Manufacture COVID-19 Vaccine Doses for Latin America
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with Eurofarma Laboratórios SA, a Brazilian biopharmaceutical company, to manufacture
Pfizer and BioNTech Initiate Rolling Submission of Supplemental Biologics License Application to U.S. FDA for Booster Dose of COMIRNATY® in Individuals 16 and Older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the
Clovis Oncology Announces Availability of and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Switzerland
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca (rucaparib) is now available and reimbursed in Switzerland. The Swiss authority responsible for the authorization and supervision
Clovis Oncology gibt die Verfügbarkeit und Erstattung von Rubraca® (Rucaparib) Tabletten für Frauen mit rezidiviertem Eierstockkrebs in der Schweiz bekannt
Clovis Oncology, Inc. (NASDAQ: CLVS) gab heute bekannt, dass Rubraca (Rucaparib) nun auch in der Schweiz erhältlich ist und die Kosten erstattet werden. Die für die Zulassung und Überwachung von
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005635/en/
Vifor Pharma and Cara Therapeutics (Nasdaq:CARA)
QIAGEN Reaches Milestone With Its Kits Used to Process More Than Three Billion Biological Samples to Date
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the number of biological samples processed with consumables kits has passed the three billion mark – a record that